Dr Howie McKibbon, CEO of Botanix Pharmaceuticals (ASX:BOT), discusses the FDA approval and market success of Sofdra, the first new chemical entity approved for primary axillary hyperhidrosis. Launched in the US in February 2024, the treatment has seen strong prescription growth, supported by extensive insurance coverage and a high-performing sales team. The company’s strategy focuses on patient adherence, facilitated by automatic prescription refills and co-pay assistance. A newly launched digital marketing initiative aims to reach millions searching for online treatment options.
05 Sep 2024 - IVE Group Limited (ASX:IGL) Managing Director Matt Aitken discusses the company's activities over the past year, touching on key metrics and projects, costs, integration of Ovato, sustainability initiatives, acquisitions of JacPak and Elastic Group, and Lasoo's performance.
27 Apr 2020 - Aus Tin Mining (ASX:ANW) CEO, Peter Williams talks farm-in agreement for exploration licences prospective for copper and gold in the Lachlan Fold Belt and proposal to divest its Granville Tin Mine.
16 Jun 2020 - Zelira Therapeutics Limited (ASX:ZLD) Managing Director Ex USA, Dr Richard Hopkins talks about the company's pipeline of products in clinical development targeting insomnia, chronic pain and autism, its model for rapid commercialisation, its go-to-market strategy and first revenues from US licensing partners.
19 Jun 2024 - Patrick Bell, CEO and Director of Finexia Financial Group (ASX:FNX) speaks to Garry Crole, CEO and Managing Director of Sequoia Financial Group (ASX:SEQ). Topics discussed include the company's Childcare Income Fund and its lending business.
10 Mar 2022 - Blair Kirkhope, Head of Specialist Investments at Sequoia Financial Group (ASX:SEQ), discusses trends in investment markets, inflation, and asset classes and sectors to watch.
14 Jun 2023 - Australia holds the world's third largest amount of vanadium, behind China and Russia, but does not supply this critical mineral into the global market. Project Director Peter Hedley from Richmond Vanadium Technology (ASX:RVT) discusses the company's progress and the vanadium industry.
31 Mar 2021 - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q) CEO and Managing Director James Graham talks about progress with the company's lead anti-infective candidate Recce 327, its expanding portfolio of synthetic anti-infectives targeting viral pathogens and a broad range of bacteria, clinical trial results and priorities for 2021.
08 Jan 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO, Dr Michael Baker, talks about the company’s plans to develop Anagrelide, for the treatment of cancer, and to commercialise its lead product ZolpiMist worldwide.
